Filters

 

Resource Type
Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC1-Related Disorders'

Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'

Read More
Metrion Biosciences appoints Lee Patterson as CEO

An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.

Read More
Celebrating 50 years of HASAWA and its impact on workplace safety

With enthusiastic engagement from staff, we’ve cultivated a robust H&S culture, ensuring we continuously prioritize the health, safety, and well-being of everyone at Metrion.

Read More
Celebrating positive male role models: International Men's Day 2024

IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.

Read More
Secondary pharmacology publication recognised as ‘Most Impactful Publication of the Year’ by the Safety Pharmacology Society

IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.

Read More
Publication in support of refining the hERG testing strategy for silencing RNA (siRNA) receives ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society

'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.

Read More
High-quality, cost-effective and rapid-turnaround, GLP testing against hERG

Metrion Biosciences provides GLP hERG testing services which crucial for drug discovery and the Investigational New Drug (IND) process. Our focus is on delivering reliable, regulatory-compliant data quickly and cost-effectively.

Read More
Importance of GLP hERG testing: Ensure data regarding a drug’s potential to cause cardiac arrhythmias is reliable, giving confidence that it can be used in regulatory decision making

The hERG gene encodes a potassium ion channel that is essential for repolarizing the cardiac action potential. Inhibition of this channel can prolong the QT interval on an electrocardiogram (ECG), leading to a condition called Torsades de Pointes (TdP), a potentially fatal arrhythmia.

Read More
The path to my industrial placement at Metrion Biosciences: Beth Sharp

I am currently studying Biomedical Sciences at the University of Manchester. Through my previous years of education, I enjoyed studying biology and engaging in practical experiments, particularly those with clinical relevance, which ultimately guided my degree selection.

Read More
Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer
Read More
1 2 3 11
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram